US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
USRE30985E
(en)
|
1978-01-01 |
1982-06-29 |
|
Serum-free cell culture media
|
US4419446A
(en)
|
1980-12-31 |
1983-12-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant DNA process utilizing a papilloma virus DNA as a vector
|
US4601978A
(en)
|
1982-11-24 |
1986-07-22 |
The Regents Of The University Of California |
Mammalian metallothionein promoter system
|
US4560655A
(en)
|
1982-12-16 |
1985-12-24 |
Immunex Corporation |
Serum-free cell culture medium and process for making same
|
US4657866A
(en)
|
1982-12-21 |
1987-04-14 |
Sudhir Kumar |
Serum-free, synthetic, completely chemically defined tissue culture media
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4767704A
(en)
|
1983-10-07 |
1988-08-30 |
Columbia University In The City Of New York |
Protein-free culture medium
|
US4965199A
(en)
|
1984-04-20 |
1990-10-23 |
Genentech, Inc. |
Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
|
GB8516415D0
(en)
|
1985-06-28 |
1985-07-31 |
Celltech Ltd |
Culture of animal cells
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US4927762A
(en)
|
1986-04-01 |
1990-05-22 |
Cell Enterprises, Inc. |
Cell culture medium with antioxidant
|
US5567610A
(en)
|
1986-09-04 |
1996-10-22 |
Bioinvent International Ab |
Method of producing human monoclonal antibodies and kit therefor
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
DE3883899T3
(en)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
CHANGED ANTIBODIES.
|
EP0308936B1
(en)
|
1987-09-23 |
1994-07-06 |
Bristol-Myers Squibb Company |
Antibody heteroconjugates for the killing of HIV-infected cells
|
ATE135397T1
(en)
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
JP2919890B2
(en)
|
1988-11-11 |
1999-07-19 |
メディカル リサーチ カウンスル |
Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
DE3920358A1
(en)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
|
DE69029036T2
(en)
|
1989-06-29 |
1997-05-22 |
Medarex Inc |
SPECIFIC REAGENTS FOR AIDS THERAPY
|
EP1690935A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5229275A
(en)
|
1990-04-26 |
1993-07-20 |
Akzo N.V. |
In-vitro method for producing antigen-specific human monoclonal antibodies
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
KR100272077B1
(en)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5122469A
(en)
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
US5264365A
(en)
|
1990-11-09 |
1993-11-23 |
Board Of Regents, The University Of Texas System |
Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
|
US5508192A
(en)
|
1990-11-09 |
1996-04-16 |
Board Of Regents, The University Of Texas System |
Bacterial host strains for producing proteolytically sensitive polypeptides
|
ATE164395T1
(en)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
DK0590058T3
(en)
|
1991-06-14 |
2004-03-29 |
Genentech Inc |
Humanized heregulin antibody
|
GB9114948D0
(en)
|
1991-07-11 |
1991-08-28 |
Pfizer Ltd |
Process for preparing sertraline intermediates
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
ES2136092T3
(en)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
JPH07501451A
(en)
|
1991-11-25 |
1995-02-16 |
エンゾン・インコーポレイテッド |
Multivalent antigen binding protein
|
EP1997894B1
(en)
|
1992-02-06 |
2011-03-30 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
US5573905A
(en)
|
1992-03-30 |
1996-11-12 |
The Scripps Research Institute |
Encoded combinatorial chemical libraries
|
AU668423B2
(en)
|
1992-08-17 |
1996-05-02 |
Genentech Inc. |
Bispecific immunoadhesins
|
DE69330523D1
(en)
|
1992-08-21 |
2001-09-06 |
Vrije Universiteit Brussel Bru |
IMMUNOGLOBULINE WITHOUT LIGHT CHAINS
|
WO1994011026A2
(en)
|
1992-11-13 |
1994-05-26 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
|
CA2163345A1
(en)
|
1993-06-16 |
1994-12-22 |
Susan Adrienne Morgan |
Antibodies
|
US5639635A
(en)
|
1994-11-03 |
1997-06-17 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
EP0794792A1
(en)
|
1994-12-02 |
1997-09-17 |
Chiron Corporation |
Method of promoting an immune response with a bispecific antibody
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
EP0739981A1
(en)
|
1995-04-25 |
1996-10-30 |
Vrije Universiteit Brussel |
Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
|
DE69637481T2
(en)
|
1995-04-27 |
2009-04-09 |
Amgen Fremont Inc. |
Human antibodies to IL-8 derived from immunized Xenomae
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
Human antibodies derived from immunized xenomice
|
US5837234A
(en)
|
1995-06-07 |
1998-11-17 |
Cytotherapeutics, Inc. |
Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
|
DE19544393A1
(en)
|
1995-11-15 |
1997-05-22 |
Hoechst Schering Agrevo Gmbh |
Synergistic herbicidal mixtures
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
WO1997038123A1
(en)
|
1996-04-05 |
1997-10-16 |
Board Of Regents, The University Of Texas System |
Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
|
ATE374248T1
(en)
|
1996-06-27 |
2007-10-15 |
Vlaams Interuniv Inst Biotech |
ANTIBODY MOLECULES THAT INTERACT SPECIFICALLY WITH THE ACTIVE CENTER OR ACTIVE Cleft of a TARGET MOLECULE
|
WO1998022141A2
(en)
|
1996-11-19 |
1998-05-28 |
Sangstat Medical Corporation |
Enhanced effects for hapten conjugated therapeutics
|
EP2305027B1
(en)
|
1996-12-03 |
2014-07-02 |
Amgen Fremont Inc. |
Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
|
ES2246069T3
(en)
|
1997-05-02 |
2006-02-01 |
Genentech, Inc. |
PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
|
US6083715A
(en)
|
1997-06-09 |
2000-07-04 |
Board Of Regents, The University Of Texas System |
Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
|
WO1998058964A1
(en)
|
1997-06-24 |
1998-12-30 |
Genentech, Inc. |
Methods and compositions for galactosylated glycoproteins
|
WO1999022764A1
(en)
|
1997-10-31 |
1999-05-14 |
Genentech, Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
ES2375931T3
(en)
|
1997-12-05 |
2012-03-07 |
The Scripps Research Institute |
HUMANIZATION OF ANTIBODY MURINO.
|
AU3596599A
(en)
|
1998-01-26 |
1999-08-09 |
Unilever Plc |
Method for producing antibody fragments
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
JP2002510481A
(en)
|
1998-04-02 |
2002-04-09 |
ジェネンテック・インコーポレーテッド |
Antibody variants and fragments thereof
|
EP2261229A3
(en)
|
1998-04-20 |
2011-03-23 |
GlycArt Biotechnology AG |
Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
|
GB9824632D0
(en)
|
1998-11-10 |
1999-01-06 |
Celltech Therapeutics Ltd |
Biological compounds
|
JP2003512019A
(en)
|
1999-01-15 |
2003-04-02 |
ジェネンテック・インコーポレーテッド |
Polypeptide variants with altered effector functions
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
ATE276359T1
(en)
|
1999-01-19 |
2004-10-15 |
Unilever Nv |
METHOD FOR PRODUCING ANTIBODY FRAGMENTS
|
ES2420835T3
(en)
|
1999-04-09 |
2013-08-27 |
Kyowa Hakko Kirin Co., Ltd. |
Procedure to control the activity of immunofunctional molecules
|
KR20020047132A
(en)
|
1999-08-24 |
2002-06-21 |
메다렉스, 인코포레이티드 |
Human ctla-4 antibodies and their uses
|
JP4668498B2
(en)
|
1999-10-19 |
2011-04-13 |
協和発酵キリン株式会社 |
Method for producing polypeptide
|
WO2001044463A1
(en)
|
1999-12-15 |
2001-06-21 |
Genentech, Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
JP2003531588A
(en)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
Multivalent antibodies and their uses
|
WO2001079442A2
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2001090190A2
(en)
|
2000-05-26 |
2001-11-29 |
National Research Council Of Canada |
Single-domain antigen-binding antibody fragments derived from llama antibodies
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
CA2953239A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
CN101940189A
(en)
|
2000-11-30 |
2011-01-12 |
米德列斯公司 |
Transgenic trasnchromosomal rodents for making human antibodies
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
CN1195779C
(en)
|
2001-05-24 |
2005-04-06 |
中国科学院遗传与发育生物学研究所 |
Double-specificity antibody resisting human ovary cancer and human CD3
|
US20060073141A1
(en)
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
EP1423510A4
(en)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
ES2337986T3
(en)
|
2001-08-10 |
2010-05-03 |
Aberdeen University |
FISHING ANTIGENS UNION DOMAINS.
|
US7371849B2
(en)
|
2001-09-13 |
2008-05-13 |
Institute For Antibodies Co., Ltd. |
Methods of constructing camel antibody libraries
|
JP2005289809A
(en)
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
Mutant heavy-chain antibody
|
ES2326964T3
(en)
|
2001-10-25 |
2009-10-22 |
Genentech, Inc. |
GLICOPROTEIN COMPOSITIONS.
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
WO2003085119A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
|
BR0309145A
(en)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Cells from which the genome is modified
|
AU2003236019A1
(en)
|
2002-04-09 |
2003-10-20 |
Kyowa Hakko Kirin Co., Ltd. |
Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
|
CA2481837A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Production process for antibody composition
|
ATE503829T1
(en)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
|
CA2481920A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Antibody composition-containing medicament
|
AU2003239966B9
(en)
|
2002-06-03 |
2010-08-26 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
JP2006504971A
(en)
|
2002-11-01 |
2006-02-09 |
ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト |
Quantitative analysis of protein isoforms by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry
|
GB0228210D0
(en)
|
2002-12-03 |
2003-01-08 |
Babraham Inst |
Single chain antibodies
|
PL212899B1
(en)
|
2002-12-16 |
2012-12-31 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
EP1585767A2
(en)
|
2003-01-16 |
2005-10-19 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2542046A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Fused protein composition
|
CA2542125A1
(en)
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
|
HUE031632T2
(en)
|
2003-11-05 |
2017-07-28 |
Roche Glycart Ag |
Antigen binding molecules with increased Fc receptor binding affinity and effector function
|
JPWO2005053742A1
(en)
|
2003-12-04 |
2007-06-28 |
協和醗酵工業株式会社 |
Medicament containing antibody composition
|
JP5128935B2
(en)
|
2004-03-31 |
2013-01-23 |
ジェネンテック, インコーポレイテッド |
Humanized anti-TGF-β antibody
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
EP2360186B1
(en)
|
2004-04-13 |
2017-08-30 |
F. Hoffmann-La Roche AG |
Anti-P-selectin antibodies
|
SI1776383T1
(en)
|
2004-07-22 |
2014-12-31 |
Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics |
Binding molecules
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
NZ580115A
(en)
|
2004-09-23 |
2010-10-29 |
Genentech Inc |
Cysteine engineered antibody light chains and conjugates
|
FR2879605B1
(en)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
PRODUCTION OF ANTIBODY FORMATS AND IMMUNOLOGICAL APPLICATIONS OF THESE FORMATS
|
WO2006138670A2
(en)
|
2005-06-16 |
2006-12-28 |
Virxsys Corporation |
Antibody complexes
|
MY169746A
(en)
|
2005-08-19 |
2019-05-14 |
Abbvie Inc |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
CA2638117A1
(en)
|
2006-01-25 |
2007-08-30 |
Erasmus University Medical Center Rotterdam |
Generation of heavy-chain only antibodies in transgenic animals
|
WO2007112940A2
(en)
|
2006-03-31 |
2007-10-11 |
Ablynx N.V. |
Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
|
TW200812616A
(en)
|
2006-05-09 |
2008-03-16 |
Genentech Inc |
Binding polypeptides with optimized scaffolds
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
CN101210048A
(en)
|
2006-12-29 |
2008-07-02 |
中国医学科学院血液学研究所 |
Anti-CD33 engineering antibody for target conjugated marrow series leukemia cell and its expression vector and use
|
CN100592373C
(en)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
Liquid crystal panel drive device and its drive method
|
PL2170959T3
(en)
|
2007-06-18 |
2014-03-31 |
Merck Sharp & Dohme |
Antibodies to human programmed death receptor pd-1
|
AU2008328779B2
(en)
|
2007-11-27 |
2014-06-05 |
Ablynx N.V. |
Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
|
CN101932608A
(en)
|
2007-11-30 |
2010-12-29 |
葛兰素集团有限公司 |
Antigen-binding constructs
|
US8592562B2
(en)
|
2008-01-07 |
2013-11-26 |
Amgen Inc. |
Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
IT1394281B1
(en)
|
2009-01-19 |
2012-06-06 |
Zardi |
PROCESS FOR THE PRODUCTION OF POLYVALENT AND POLYSPECIFIC MELTING PROTEINS USING AS A STRUCTURE CARRYING OUT THE UTEROGLOBIN AND PRODUCTS OBTAINED SO.
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
BRPI1014089A2
(en)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
multispecific antibodies comprising full length antibodies and single chain fab fragments
|
GB201005063D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
DK2509409T3
(en)
|
2009-12-10 |
2016-11-14 |
Regeneron Pharma |
MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
US8993731B2
(en)
|
2010-03-11 |
2015-03-31 |
Ucb Biopharma Sprl |
PD-1 antibody
|
JP6048972B2
(en)
|
2010-04-23 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
Production of heteromultimeric proteins
|
UA112062C2
(en)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
CD33-Binding Agent
|
HUE039209T2
(en)
|
2011-03-31 |
2018-12-28 |
Merck Sharp & Dohme |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
JP5987053B2
(en)
|
2011-05-12 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
Multiple reaction monitoring LC-MS / MS method for detecting therapeutic antibodies in animal samples using framework signature peptides
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
BR112014002353B1
(en)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT
|
TWI679212B
(en)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
Binding molecules for e3 of bcma and cd3
|
WO2013112986A1
(en)
|
2012-01-27 |
2013-08-01 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
KR101911438B1
(en)
|
2012-10-31 |
2018-10-24 |
삼성전자주식회사 |
Bispecific antigen binding protein complex and preparation methods of bispecific antibodies
|
CA2903096A1
(en)
|
2013-03-05 |
2014-09-12 |
Baylor College Of Medicine |
Oncolytic virus
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
CN104250302B
(en)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
The anti-antibody of PD 1 and its application
|
MX2016003292A
(en)
*
|
2013-09-13 |
2016-06-24 |
Beigene Ltd |
Anti-pd1 antibodies and their use as therapeutics and diagnostics.
|
US10350275B2
(en)
|
2013-09-21 |
2019-07-16 |
Advantagene, Inc. |
Methods of cytotoxic gene therapy to treat tumors
|
EP3065772A4
(en)
|
2013-11-05 |
2017-09-13 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
JOP20200094A1
(en)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
Antibody molecules to pd-1 and uses thereof
|
US20170037125A1
(en)
|
2014-02-04 |
2017-02-09 |
Incyte Corporation |
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
|
BR112016021572A2
(en)
|
2014-03-21 |
2017-10-03 |
Regeneron Pharma |
METHODS FOR PREPARING A GENETICALLY MODIFIED NON-HUMAN ANIMAL AND FOR PRODUCING BINDING PROTEINS, HYBRIDOMA, NUCLEIC ACID, CELL, AND, BINDING PROTEIN
|
HRP20220738T1
(en)
|
2014-08-11 |
2022-08-19 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
|
EP3186277B1
(en)
|
2014-08-27 |
2020-10-07 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
WO2016040868A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
AU2015332533B2
(en)
|
2014-10-14 |
2018-08-30 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
|
CN107001478B
(en)
|
2014-10-14 |
2022-01-11 |
诺华股份有限公司 |
Antibody molecules against PD-L1 and uses thereof
|
US10822414B2
(en)
*
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
AU2015350242A1
(en)
|
2014-11-17 |
2017-06-29 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
|
US10426847B2
(en)
|
2015-03-26 |
2019-10-01 |
Oncosec Medical Incorporated |
Method for the treatment of malignancies
|
WO2016168769A1
(en)
|
2015-04-15 |
2016-10-20 |
The California Institute For Biomedical Research |
Chimeric receptor t cell switches for her2
|
JP6688551B2
(en)
|
2015-05-21 |
2020-04-28 |
ハープーン セラピューティクス,インク. |
Trispecific binding proteins and methods of use
|
TWI773646B
(en)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
Lag-3-binding molecules and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
JP6996983B2
(en)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
Anti-CLL-1 antibody and how to use
|
WO2017024515A1
(en)
*
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
RU2729830C2
(en)
*
|
2015-08-11 |
2020-08-12 |
Уси Байолоджикс (Кайман) Инк. |
Novel anti-pd-1 antibodies
|
JP6861418B2
(en)
|
2015-09-02 |
2021-04-28 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド |
Antibodies specific for human T cell immunoglobulin and ITIM domain (TIGIT)
|
CN108290946B
(en)
|
2015-09-25 |
2021-09-28 |
豪夫迈·罗氏有限公司 |
anti-TIGIT antibodies and methods of use
|
DK3356401T3
(en)
|
2015-09-30 |
2020-09-07 |
Igm Biosciences Inc |
BINDING MOLECULES WITH MODIFIED J-CHAIN
|
MX2018003898A
(en)
|
2015-10-01 |
2018-12-17 |
Potenza Therapeutics Inc |
Anti-tigit antigen-binding proteins and methods of use thereof.
|
KR102220275B1
(en)
*
|
2015-11-18 |
2021-02-26 |
머크 샤프 앤드 돔 코포레이션 |
Pd1 and/or lag3 binders
|
MA43258A
(en)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme |
BINDERS PD1 / CTLA4
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
ES2847155T3
(en)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Multispecific molecules targeting CLL-1
|
JP7438662B2
(en)
|
2016-01-25 |
2024-02-27 |
ジェネンテック, インコーポレイテッド |
Method for assaying T cell-dependent bispecific antibodies
|
CN105754990A
(en)
|
2016-01-29 |
2016-07-13 |
深圳精准医疗科技有限公司 |
Preparation method and application of PD-1/CTLA-4 (programmed death-1/cytotoxic T lymphocyte antigen-4) bispecific antibody
|
AU2017222700B2
(en)
|
2016-02-26 |
2018-09-27 |
Imunexus Therapeutics Limited |
Multi-specific molecules
|
WO2017165681A1
(en)
|
2016-03-24 |
2017-09-28 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
AU2017266298B2
(en)
|
2016-05-18 |
2024-01-04 |
Boehringer Ingelheim International Gmbh |
Anti PD-1 and anti-LAG3 antibodies for cancer treatment
|
CN107400166A
(en)
|
2016-05-19 |
2017-11-28 |
苏州康宁杰瑞生物科技有限公司 |
for CTLA4 single domain antibody and its derived protein
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CA2937157A1
(en)
|
2016-07-25 |
2018-01-25 |
Ucl Business Plc |
Protein-based t-cell receptor knockdown
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
CN106939050B
(en)
*
|
2017-03-27 |
2019-05-10 |
顺昊细胞生物技术(天津)股份有限公司 |
anti-PD 1 and CD19 bispecific antibodies and uses thereof
|
EA039662B1
(en)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Antibodies specific to cd47 and pd-l1
|
CN109897111B
(en)
|
2017-12-08 |
2021-02-23 |
杭州翰思生物医药有限公司 |
Bispecific antibody against PD-1/CD47 and application thereof
|
EP3733716A4
(en)
|
2017-12-26 |
2021-11-24 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody fc region as backbone and use thereof
|
CN117050184A
(en)
|
2017-12-28 |
2023-11-14 |
南京传奇生物科技有限公司 |
Single domain antibodies to TIGIT and variants thereof
|
CN111836832A
(en)
|
2018-01-08 |
2020-10-27 |
南京传奇生物科技有限公司 |
Multispecific antigen binding proteins and methods of use thereof
|
JP7366908B2
(en)
|
2018-01-15 |
2023-10-23 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Single domain antibodies against PD-1 and variants thereof
|
CN108047333B
(en)
|
2018-01-15 |
2021-05-25 |
浙江阿思科力生物科技有限公司 |
Specific antibody with CD33 as target, CAR-NK cell, and preparation and application thereof
|
WO2019179434A1
(en)
|
2018-03-20 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/cd47 antibody molecules
|
CA3093034A1
(en)
|
2018-03-30 |
2019-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against lag-3 and uses thereof
|
EP3850013A4
(en)
|
2018-09-10 |
2022-10-05 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against cll1 and constructs thereof
|
CN114072426B
(en)
|
2019-07-08 |
2024-01-26 |
南京金斯瑞生物科技有限公司 |
anti-CD 47/anti-PD-1 bispecific antibody and preparation method and application thereof
|